LPS-CXCL10 Predicts Responses to Bortezomib in Myeloma Patients
Watanabe, Takashi National Cancer Center Hospital|Komaki City Hospital
Mitsuhashi, Masato Hitachi Chemical Research Center
Sagawa, Morihiko Saitama Medical University
Ri, Masaki Nagoya City University
Suzuki, Kenshi Japanese Red Cross Medical Center
安倍, 正博 Tokushima University 徳島大学 教育研究者総覧 KAKEN研究者をさがす
Ohmachi, Ken Tokai University
Nakagawa, Yasunori Japanese Red Cross Medical Center
中村, 信元 Tokushima University 徳島大学 教育研究者総覧 KAKEN研究者をさがす
Chosa, Mizuki National Cancer Center Hospital
Iida, Shinsuke Nagoya City University
Kizaki, Masahiro Saitama Medical University
To identify predictive biomarkers for clinical responses to bortezomib treatment, 0.06 mL of each whole blood without any cell separation procedures was stimulated ex vivo using five agents, and eight mRNAs were quantified. In six centers, heparinized peripheral blood was prospectively obtained from 80 previously treated or untreated, symptomatic multiple myeloma (MM) patients with measurable levels of M-proteins. The blood sample was procured prior to treatment as well as 2-3 days and 1-3 weeks after the first dose of bortezomib, which was intravenously administered biweekly or weekly, during the first cycle. Six stimulant-mRNA combinations; that is, lipopolysaccharide (LPS)-granulocyte-macrophage colony-stimulating factor (GM-CSF), LPS-CXCL chemokine 10 (CXCL10), LPS-CCL chemokine 4 (CCL4), phytohemagglutinin-CCL4, zymosan A (ZA)-GMCSF and ZA-CCL4 showed significantly higher induction in the complete and very good partial response group than in the stable and progressive disease group, as determined by both parametric (t-test) and non-parametric (unpaired Mann-Whitney test) tests. Moreover, LPS-induced CXCL10 mRNA expression was significantly suppressed 2-3 days after the first dose of bortezomib in all patients, as determined by both parametric (t-test) and non-parametric (paired Wilcoxon test) tests, whereas the complete and very good partial response group showed sustained suppression 1-3 weeks after the first dose. Thus, pretreatment LPS-CXCL10 mRNA and/or the six combinations may serve as potential biomarkers for the response to bortezomib treatment in MM patients.
© 2015 Watanabe et al. This is an open access article distributed under the terms of the Creative Commons Attribution License(https://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
pone_10_6_e0128662.pdf 1.2 MB